Preliminary Results of a Phase Ib Study of Duvelisib in Combination with FCR (dFCR) in Previously Untreated, Younger Patients with CLL
Matthew S. Davids(Dana-Farber Cancer Institute), Jennifer R. Brown(Dana-Farber Cancer Institute), Leslie Cowen(Dana-Farber Cancer Institute), Haesook T. Kim(Dana-Farber Cancer Institute), Karen Francoeur(Dana-Farber Cancer Institute), David C. Fisher(Dana-Farber Cancer Institute), Jeffrey Hellman(Dana-Farber Cancer Institute), Elizabeth Gilbert(Dana-Farber Cancer Institute), Jon Arnason(Beth Israel Deaconess Medical Center)
Cited by 12
Related Papers
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|890
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
|Journal of Clinical Oncology|2017|752